{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-034836","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.861953+00:00","generated_at":"2026-06-21T07:36:08.224127+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ensysce Biosciences prices $4.1M public offering of 2.9M shares and 5.8M warrants","bullets":["Gross proceeds of ~$4.1M from offering of 2,900,000 shares (or pre-funded warrants) and 5,800,000 warrants at $1.40 combined price.","Each warrant exercisable immediately at $1.40/share, expires 5 years from issuance.","Underwriter (Lake Street Capital) granted 45-day option to purchase up to 342,000 additional shares and 870,000 warrants.","20% of gross proceeds to repay convertible notes; remainder for clinical development and working capital.","Company directors and officers signed 90-day lock-up agreements restricting stock sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-034836","json":"https://secwatch.observer/filing/0001493152-22-034836.json","markdown":"https://secwatch.observer/filing/0001493152-22-034836.md","text":"https://secwatch.observer/filing/0001493152-22-034836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222034836/0001493152-22-034836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222034836/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:36:08.224127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ae2f21ce5e1bbdc1ccaa34098a4e869a46362ff","claim":"Ensysce Biosciences, Inc. entered into Underwriting Agreement with Lake Street Capital Management, LLC valued at approximately $4.1 million (effective 2022-12-07).","evidence_excerpt":"On December 7, 2022, Ensysce Biosciences, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Lake Street Capital Management, LLC (the “ Underwriter ”), pursuant to which the Company agreed to issue and sell (i) 2,280,000 shares (the “ Firm Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), (ii) pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 620,000 shares of Common Stock and (iii) warrants to purchase 5,800,000 shares of Common Stock (the “ Common Warrants ” and, collectively with the Pre-Funded Warrants, the “ Warrants ”) to the Underwriter in a public offering (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222034836/0001493152-22-034836-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Lake Street Capital Management, LLC"},{"label":"Value","value":"approximately $4.1 million"},{"label":"Effective","value":"2022-12-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}